Literature DB >> 12690924

A case of cardiac localization of graft-versus-host disease after allogenic bone marrow transplantation.

Manuela Cereda1, Giuseppe Trocino, Enrico Maria Pogliani, Riccardo Schiavina.   

Abstract

A 29-year-old male developed symptoms and signs of heart failure shortly after allogenic bone marrow transplantation for chronic myelogenous leukemia. Echocardiographic evaluation showed left ventricular wall thickening, a left ventricular restrictive filling pattern and pericardial effusion. Cardiac magnetic resonance revealed nodular areas compatible with lymphocyte infiltration. The hypothesis of cardiac graft-versus-host disease was supported by the reversibility of all the abnormalities after specific treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12690924

Source DB:  PubMed          Journal:  Ital Heart J        ISSN: 1129-471X


  4 in total

1.  Pericardial effusion as a complication of chronic graft versus host disease.

Authors:  Keaton Nasser; Kshipra Joshi; Ella Starobinska
Journal:  BMJ Case Rep       Date:  2018-12-14

2.  Large pericardial effusion as a complication in adults undergoing SCT.

Authors:  M Norkin; V Ratanatharathorn; L Ayash; M H Abidi; Z Al-Kadhimi; L G Lum; J P Uberti
Journal:  Bone Marrow Transplant       Date:  2010-11-29       Impact factor: 5.483

Review 3.  Myocarditis with Advanced Atrioventricular Block after Allogeneic Stem Cell Transplantation: A Case Report and Literature Review.

Authors:  Masahiko Sumi; Mari Kitahara; Tsutomu Shishido; Hiroko Kazumoto; Nozomu Uematsu; Takehiko Kirihara; Keijiro Sato; Toshimitsu Ueki; Yuki Hiroshima; Kunihiko Shimizu; Hikaru Kobayashi
Journal:  Intern Med       Date:  2019-08-28       Impact factor: 1.271

4.  Factors Affecting Survival in Children With Pericardial Effusion After Hematopoietic Stem Cell Transplantation.

Authors:  Tang-Her Jaing; Shih-Hsiang Chen; Yu-Chuan Wen; Tsung-Yen Chang; Dai-Yun Tsai; Hung-Tao Chung; Pei-Kwei Tsay
Journal:  Cell Transplant       Date:  2017-11       Impact factor: 4.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.